Stephens Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $2.00

Definitive Healthcare (NASDAQ:DH) had its price objective cut by Stephens from $3.00 to $2.00 in a research report released on Friday,Benzinga reports. They currently have an equal weight rating on the stock.

DH has been the topic of a number of other research reports. Wall Street Zen cut shares of Definitive Healthcare from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 28th. Morgan Stanley reiterated an “underperform” rating and issued a $3.50 price target on shares of Definitive Healthcare in a research report on Thursday, December 18th. Canaccord Genuity Group dropped their price objective on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Monday, November 10th. William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $3.52.

Definitive Healthcare Price Performance

Shares of NASDAQ:DH opened at $1.28 on Friday. The company has a 50-day moving average price of $2.18 and a two-hundred day moving average price of $2.87. Definitive Healthcare has a twelve month low of $1.14 and a twelve month high of $4.70. The company has a quick ratio of 1.64, a current ratio of 1.64 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $180.94 million, a PE ratio of -1.02 and a beta of 1.66.

Institutional Trading of Definitive Healthcare

Several institutional investors and hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund grew its holdings in shares of Definitive Healthcare by 0.4% during the second quarter. New York State Common Retirement Fund now owns 766,433 shares of the company’s stock worth $2,989,000 after purchasing an additional 3,066 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Definitive Healthcare by 32.9% during the third quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after purchasing an additional 4,407 shares during the last quarter. State of Alaska Department of Revenue grew its stake in Definitive Healthcare by 109.3% in the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock worth $32,000 after buying an additional 5,970 shares in the last quarter. Invesco Ltd. grew its stake in Definitive Healthcare by 5.8% in the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock worth $337,000 after buying an additional 6,400 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Definitive Healthcare in the 2nd quarter worth $32,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

More Definitive Healthcare News

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Q4 revenue came in roughly in-line to slightly above estimates (reported ~$61.5M vs. some analyst estimates around $59–61M), showing top-line stability versus a year ago. Read More.
• Positive Sentiment: Cash and cash equivalents increased year-over-year (reported ~$163.6M), which supports near-term liquidity. Read More.
• Neutral Sentiment: Reported GAAP EPS results were reported as meeting some consensus figures (sources show EPS in-line with a $0.06 consensus), so headline EPS didn’t surprise to the upside. Read More.
• Neutral Sentiment: Brokerage consensus has settled around a “Hold” average recommendation, reflecting mixed views across analysts. Read More.
• Negative Sentiment: The company cut guidance: Q1 FY2026 EPS guidance (~$0.03) and revenue guidance ($54M–$56M) both sit below consensus, and full‑year 2026 guidance ($0.14–$0.17 EPS; $220M–$226M revenue) also trails Street expectations — the primary driver of today’s downside. Read More.
• Negative Sentiment: Analysts lowered price targets and kept cautious ratings (Canaccord cut its target from $4.00 to $3.00 with a Hold; Stephens trimmed its target to $2.00 with Equal Weight), amplifying selling pressure. Read More.
• Negative Sentiment: Underlying profitability metrics showed deterioration in some reports (wider operating loss and larger net loss year-over-year), and multiple institutional holders trimmed positions in the latest quarter, suggesting reduced confidence from larger investors. Read More.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.